These days, one can almost be convinced of the reality of a truly efficient market, one that brings together buyers and sellers, matching excess capacity with need. The Internet promises to make this possible, by acting as the ultimate go-between. It is not only the purveyors of products that have realized the potential of the Internet's connectivity. Recently, several sites have gone up to facilitate the buying and selling of certain fungible but less tangible assets of R&D based companies. Yet2.com, Pharmalicensing.com,and PL-X.com all have web sites that seek to match buyers and sellers in technology transfer. PharmaUniverse.com hopes to create an efficient market for other pharmaceuticals assets like short-dated inventory or manufacturing capacity.
The Web, as E-Bay has definitively shown, can create relatively
efficient markets, bringing together diverse buyers and sellers.
Health care has seen a number of marketing and distribution plays,
like Ventro Corp. , Neoforma.com
Inc. , and MedAssets.com Inc.
Now companies are starting up to broker the often less obvious assets of the industry. The founders of drug delivery...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
The drugmaker announced it would work with the tech giant to deploy a supercomputer that it will use to train AI models and enhance drug discovery, development and manufacturing.
Dr. Reddy's doesn’t fully rule out "queries" from the Canadian regulator for generic semaglutide, though it is confident of selling “all its capacity” for the GLP-1 across target markets. A backup CMO site in the US for abatacept is expected to mitigate risks amid tariff and other uncertainties.
The US FDA’s 'Official Action Indicated' tag on Novo Nordisk’s Catalent Indiana plant has led analysts to push their approval timelines for pending applications by Regeneron and Scholar Rock.
Lupin’s plan for a manufacturing unit in the US follows Trump’s threat of tariffs on branded or patented drugs unless a company is “building” a plant in the US. Will similar investments from Indian firms follow?
Do US FDA’s efforts at simplifying the biosimilar pathway create more competition and threaten Aurobindo Pharma's return on investments? Management speaks on this, biosimilar filing plans and deal strategy at the Q2 FY26 earnings call
South Korea’s two biosimilars giants have laid out differing strategies to pursue innovative drug R&D, although both are positioning ADCs as a core focus.
Another strong quarter keeps AstraZeneca on track to meet its $80bn sales ambition, and its CEO maintains the recent Trump deal provides pricing reassurance, despite a lack of details so far.
